Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Medinger

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
International Journal of Oncology|December 15, 2010
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma modelM Medinger, N Esser, J Soltau, et al.
Bone Marrow Transplantation|June 27, 2017
Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantationA Tichelli, S Gerull, A Holbro, et al.
Bone Marrow Transplantation|August 13, 2008
Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?A Buser, M Stern, C Arber, et al.
Bone Marrow Transplantation|January 10, 2017
Revisiting nutritional support for allogeneic hematologic stem cell transplantation-a systematic reviewA Baumgartner, A Bargetzi, N Zueger, et al.
Bone Marrow Transplantation|June 30, 2015
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantationL Binkert, M Medinger, J P Halter, et al.
Bone Marrow Transplantation|June 9, 2015
High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparitiesJ R Passweg, U Schanz, Y Chalandon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsJ Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
International Journal of Oncology|December 15, 2010
Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma modelM Medinger, N Esser, J Soltau, et al.
Bone Marrow Transplantation|June 27, 2017
Inability to work and need for disability pension among long-term survivors of hematopoietic stem cell transplantationA Tichelli, S Gerull, A Holbro, et al.
Bone Marrow Transplantation|August 13, 2008
Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?A Buser, M Stern, C Arber, et al.
Bone Marrow Transplantation|January 10, 2017
Revisiting nutritional support for allogeneic hematologic stem cell transplantation-a systematic reviewA Baumgartner, A Bargetzi, N Zueger, et al.
Bone Marrow Transplantation|June 30, 2015
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantationL Binkert, M Medinger, J P Halter, et al.
Bone Marrow Transplantation|June 9, 2015
High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparitiesJ R Passweg, U Schanz, Y Chalandon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2005
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsJ Drevs, U Zirrgiebel, C I M Schmidt-Gersbach, et al.
Pageof 2